1. Home
  2. NVS
  3. NVS News

Latest Novartis AG (NVS) News on July 13, 2025

FDA willing to trade faster drug reviews for lower prices, Bloomberg reports
NVS

TipRanks

21 hours ago

FDA willing to trade faster drug reviews for lower prices, Bloomberg reports

Portfolio manager sees long-term AI upside in healthcare sector
NVS

Reuters Videos

2 days ago

Portfolio manager sees long-term AI upside in healthcare sector

NVS

MT Newswires

2 days ago

Sector Update: Health Care Stocks Retreat Late Afternoon

NVS

MT Newswires

2 days ago

Novartis Loses Patent Infringement Suit Against MSN Pharmaceuticals for Entresto Generic

NVS

MT Newswires

2 days ago

Market Chatter: FDA May Fast Track Drug Reviews for Lower US Prices

Bayer Wins Hormone-Free Treatment Approval for Women in the UK
NVS

Zacks

2 days ago

Bayer Wins Hormone-Free Treatment Approval for Women in the UK

Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx® for hidradenitis suppurativa (HS)
NVS

CNW Group

3 days ago

Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx® for hidradenitis suppurativa (HS)

Alcohol Related Liver Disease Market Forecast, 2025-2035 | Personalized Medicine Transforming ARLD Treatment Landscape
NVS

GlobeNewswire

3 days ago

Alcohol Related Liver Disease Market Forecast, 2025-2035 | Personalized Medicine Transforming ARLD Treatment Landscape

Pharma Companies Remain Calm Amid Fresh Tariff Threat by Trump
NVS

Zacks

3 days ago

Pharma Companies Remain Calm Amid Fresh Tariff Threat by Trump

Renasant Bio, chasing drugs for ADPKD, raises $55M in seed funding
NVS

BioPharma Dive

3 days ago

Renasant Bio, chasing drugs for ADPKD, raises $55M in seed funding

$14 Billion Cell and Gene Therapy Market to Double by 2030, Driven by Oncology and RNA Breakthroughs, reports Kalorama Information
NVS

PR Newswire

4 days ago

$14 Billion Cell and Gene Therapy Market to Double by 2030, Driven by Oncology and RNA Breakthroughs, reports Kalorama Information

Sironax Grants Novartis Exclusive Option to Acquire its Brain Delivery Platform While Retaining Rights to Advance Selected Therapeutic Assets
NVS

PR Newswire

4 days ago

Sironax Grants Novartis Exclusive Option to Acquire its Brain Delivery Platform While Retaining Rights to Advance Selected Therapeutic Assets

Trump's Drug Tariffs: Where Does the U.S. Import Pharmaceuticals From?
NVS

The Wall Street Journal

4 days ago

Trump's Drug Tariffs: Where Does the U.S. Import Pharmaceuticals From?

As its cancer vaccine moves through the clinic, Transgene sets sights on manufacturing
NVS

Pharma Voice

4 days ago

As its cancer vaccine moves through the clinic, Transgene sets sights on manufacturing

NVS

MT Newswires

5 days ago

Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs

Finally: A malaria drug made just for babies has been approved—here’s why it matters
NVS

FastCompany

5 days ago

Finally: A malaria drug made just for babies has been approved—here’s why it matters

Ascentage Pharma Names CFO & SVP of Global Corporate Development & Finance
NVS

Exec Edge

5 days ago

Ascentage Pharma Names CFO & SVP of Global Corporate Development & Finance

Why Novartis (NVS) is a Top Value Stock for the Long-Term
NVS

Zacks

5 days ago

Why Novartis (NVS) is a Top Value Stock for the Long-Term

NVS

MT Newswires

5 days ago

Novartis Gets Swiss Approval for Malaria Drug for Infants

Swissmedic approves Novartis’ malaria medicine for babies
NVS

Pharmaceutical Technology

5 days ago

Swissmedic approves Novartis’ malaria medicine for babies

Novartis receives approval for first malaria medicine for newborn babies and young infants
NVS

GlobeNewswire

5 days ago

Novartis receives approval for first malaria medicine for newborn babies and young infants

NVS

MT Newswires

6 days ago

Sector Update: Health Care

Here's Why Novartis (NVS) is a Strong Momentum Stock
NVS

Zacks

6 days ago

Here's Why Novartis (NVS) is a Strong Momentum Stock

Novartis’ Cosentyx shows no benefit in Phase III GCA trial
NVS

Clinical Trials Arena

9 days ago

Novartis’ Cosentyx shows no benefit in Phase III GCA trial

Switzerland seeks trade deal with Trump without getting into EU bind
NVS

Reuters

10 days ago

Switzerland seeks trade deal with Trump without getting into EU bind

Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study
NVS

Zacks

10 days ago

Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study

FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug
NVS

Zacks

10 days ago

FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug

Business and Investment Opportunities in Nuclear Medicine 2025-2030: North America Leads, Asia-Pacific Races
NVS

GlobeNewswire

10 days ago

Business and Investment Opportunities in Nuclear Medicine 2025-2030: North America Leads, Asia-Pacific Races

NVS

MT Newswires

10 days ago

Novartis Says Cosentyx Fails to Meet Primary Endpoint in Phase 3 Giant Cell Arteritis Study

Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
NVS

PR Newswire

10 days ago

Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)

Actinium Highlights ATNM 400 Progress at SNMMI Conference
NVS

Insider Monkey

10 days ago

Actinium Highlights ATNM 400 Progress at SNMMI Conference

Buy These 5 Low-Leverage Stocks Amid Wall Street's Tricky July Start
NVS

Zacks

11 days ago

Buy These 5 Low-Leverage Stocks Amid Wall Street's Tricky July Start

What's Fueling Tempus AI's Explosive Sales Growth?
NVS

Zacks

11 days ago

What's Fueling Tempus AI's Explosive Sales Growth?

Can China sustain a surge in oncology drug innovation?
NVS

Pharma Voice

11 days ago

Can China sustain a surge in oncology drug innovation?

Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock?
NVS

Zacks

12 days ago

Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock?

Novartis AG (NVS) Hits Fresh High: Is There Still Room to Run?
NVS

Zacks

12 days ago

Novartis AG (NVS) Hits Fresh High: Is There Still Room to Run?

Novartis (NVS) Acquires Regulus Therapeutics for $1.7 Billion
NVS

Insider Monkey

15 days ago

Novartis (NVS) Acquires Regulus Therapeutics for $1.7 Billion

Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
NVS

Zacks

16 days ago

Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?

Incyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role?
NVS

Investor's Business Daily

17 days ago

Incyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role?

Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes
NVS

Investor's Business Daily

17 days ago

Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes

Incyte replaces CEO Hoppenot with dealmaker Meury
NVS

BioPharma Dive

17 days ago

Incyte replaces CEO Hoppenot with dealmaker Meury

Kashiv BioSciences reports positive results from trial of Xolair biosimilar
NVS

Clinical Trials Arena

17 days ago

Kashiv BioSciences reports positive results from trial of Xolair biosimilar

ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease
NVS

GlobeNewswire

17 days ago

ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease

Retinitis Pigmentosa Research Report 2025: $25+ Bn Market Opportunities and Strategies to 2034 - Gene Therapy Poised as Fastest Growing Treatment Segment, Strategic Collaborations Drive Advancements
NVS

GlobeNewswire

17 days ago

Retinitis Pigmentosa Research Report 2025: $25+ Bn Market Opportunities and Strategies to 2034 - Gene Therapy Poised as Fastest Growing Treatment Segment, Strategic Collaborations Drive Advancements

NVS

Pharmaceutical Technology

17 days ago

Novartis concludes Regulus Therapeutics acquisition

Can Biogen Save Even More Kids With This New Drug?
NVS

Investor's Business Daily

18 days ago

Can Biogen Save Even More Kids With This New Drug?

Novartis completes acquisition of Regulus Therapeutics
NVS

GlobeNewswire

18 days ago

Novartis completes acquisition of Regulus Therapeutics

Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug?
NVS

Investor's Business Daily

18 days ago

Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug?

NVS

MT Newswires

18 days ago

Alvotech Says Proposed Xolair Biosimilar Study Meets Primary Endpoint

Novartis announces expiration of Regulus Therapeutics tender offer
NVS

GlobeNewswire

18 days ago

Novartis announces expiration of Regulus Therapeutics tender offer

Novartis AG (NVS): A Bull Case Theory
NVS

Insider Monkey

19 days ago

Novartis AG (NVS): A Bull Case Theory

Top Analyst Reports for JPMorgan, Novartis & AT&T
NVS

Zacks

19 days ago

Top Analyst Reports for JPMorgan, Novartis & AT&T

Brain Cancer Market Research Report 2025-2035 | Growing Shifts Toward Targeted Therapies and Immunotherapy Over Traditional Methods
NVS

GlobeNewswire

19 days ago

Brain Cancer Market Research Report 2025-2035 | Growing Shifts Toward Targeted Therapies and Immunotherapy Over Traditional Methods

Gene and Cell Therapies Targeting CNS Disorders Market Research 2025-2035 | Technological Advancements in Precision Delivery Drive Growth, High Costs Challenging Accessibility
NVS

GlobeNewswire

19 days ago

Gene and Cell Therapies Targeting CNS Disorders Market Research 2025-2035 | Technological Advancements in Precision Delivery Drive Growth, High Costs Challenging Accessibility

Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer
NVS

GlobeNewswire

20 days ago

Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer

Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street.
NVS

Barrons.com

23 days ago

Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street.

Novartis’ ribociclib approved in Canada for early breast cancer
NVS

Pharmaceutical Technology

23 days ago

Novartis’ ribociclib approved in Canada for early breast cancer

NYSE Content Advisory: Pre-Market update + Wall Street reopens after Juneteenth
NVS

PR Newswire

23 days ago

NYSE Content Advisory: Pre-Market update + Wall Street reopens after Juneteenth

NYSE Content Advisory: Pre-Market update + Wall Street reopens after Juneteenth
NVS

CNW Group

23 days ago

NYSE Content Advisory: Pre-Market update + Wall Street reopens after Juneteenth

FDA Approves Gilead's Twice-Yearly Shot for HIV Prevention
NVS

Zacks

24 days ago

FDA Approves Gilead's Twice-Yearly Shot for HIV Prevention

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
NVS

Zacks

24 days ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Can Casgevy Deliver a Turnaround for CRISPR Therapeutics?
NVS

Zacks

24 days ago

Can Casgevy Deliver a Turnaround for CRISPR Therapeutics?

Gene Therapy Has Lost Support on Wall Street. There’s Still Hope for Big Cures.
NVS

Barrons.com

24 days ago

Gene Therapy Has Lost Support on Wall Street. There’s Still Hope for Big Cures.

Trump administration weighs crackdown on pharma ads, Bloomberg says
NVS

TipRanks

25 days ago

Trump administration weighs crackdown on pharma ads, Bloomberg says

Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data
NVS

Insider Monkey

a month ago

Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data

NVS

MT Newswires

a month ago

Market Chatter: Trump Administration to Consider Pharma Advertising Crackdown

Maxion Therapeutics Appoints Dr. Stefan Härtle as Chief Development Officer
NVS

GlobeNewswire

a month ago

Maxion Therapeutics Appoints Dr. Stefan Härtle as Chief Development Officer

RHHBY to Advance Parkinson's Disease Drug to Late-Stage Development
NVS

Zacks

a month ago

RHHBY to Advance Parkinson's Disease Drug to Late-Stage Development

5 Large Drug Stocks That Are Poised to Ride on Sector Recovery
NVS

Zacks

a month ago

5 Large Drug Stocks That Are Poised to Ride on Sector Recovery

Buy These 5 Low-Leverage Stocks Amid Fresh Iran-Israel War
NVS

Zacks

a month ago

Buy These 5 Low-Leverage Stocks Amid Fresh Iran-Israel War

Berenberg Bank Maintains a Hold Rating on Novartis (NVS)
NVS

Insider Monkey

a month ago

Berenberg Bank Maintains a Hold Rating on Novartis (NVS)

Senators to propose ban on drug ads to consumers, WSJ reports
NVS

TipRanks

a month ago

Senators to propose ban on drug ads to consumers, WSJ reports

Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?
NVS

Zacks

a month ago

Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?

NVS

Clinical Trials Arena

a month ago

Novartis reports positive results from Phase IIIB study of iptacopan for PNH

NVS

Morningstar Research

a month ago

Analyst Report: Novartis AG

NVS

MT Newswires

a month ago

Novartis Reports 'Significant' Improvements in Study of Fabhalta to Treat PNH

Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH
NVS

GlobeNewswire

a month ago

Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH

Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel
NVS

TipRanks

a month ago

Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel

Top Cancer Stocks to Supercharge Your 2025 Portfolio
NVS

Zacks

a month ago

Top Cancer Stocks to Supercharge Your 2025 Portfolio

The former Wall Street analyst shaping Novartis’ big-picture strategy
NVS

Pharma Voice

a month ago

The former Wall Street analyst shaping Novartis’ big-picture strategy

Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
NVS

Zacks

a month ago

Why Novartis (NVS) is a Top Momentum Stock for the Long-Term

Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year?
NVS

Zacks

a month ago

Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year?

Acquisitions, Licensing Deals Take Centerstage in Pharma/Biotech Space
NVS

Zacks

a month ago

Acquisitions, Licensing Deals Take Centerstage in Pharma/Biotech Space

Novartis (NVS) Could Be a Great Choice
NVS

Zacks

a month ago

Novartis (NVS) Could Be a Great Choice

2 Dividend Growth Stocks to Buy and Hold Forever
NVS

Motley Fool

a month ago

2 Dividend Growth Stocks to Buy and Hold Forever

Novartis reports topline outcomes from trial of Pluvicto for prostate cancer
NVS

Clinical Trials Arena

a month ago

Novartis reports topline outcomes from trial of Pluvicto for prostate cancer

ASCO25: Novartis hopes Scemblix becomes new standard for CML-CP
NVS

Clinical Trials Arena

a month ago

ASCO25: Novartis hopes Scemblix becomes new standard for CML-CP

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
NVS

Zacks

a month ago

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Zacks.com featured highlights Novartis, ENGIE, MasTec, Dorman Products and Sterling Infrastructure
NVS

Zacks

a month ago

Zacks.com featured highlights Novartis, ENGIE, MasTec, Dorman Products and Sterling Infrastructure

NVS

MT Newswires

a month ago

Novartis Reports New Data From Phase 2 Trial of Kisqali in Breast Cancer

NVS

MT Newswires

a month ago

Novartis Says Pluvicto Shows Benefit in Early Prostate Cancer Study

Novartis' Pluvicto shown to slow prostate cancer in earlier setting
NVS

Reuters

a month ago

Novartis' Pluvicto shown to slow prostate cancer in earlier setting

Novartis’s Cancer Treatment Pluvicto Shows Positive Results in Trial
NVS

The Wall Street Journal

a month ago

Novartis’s Cancer Treatment Pluvicto Shows Positive Results in Trial

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
NVS

GlobeNewswire

a month ago

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis
NVS

GlobeNewswire

a month ago

Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis

Buy These 5 Low-Leverage Stocks Amid Volatile Market Sentiment
NVS

Zacks

a month ago

Buy These 5 Low-Leverage Stocks Amid Volatile Market Sentiment

What Makes Novartis AG (NVS) a Differentiated Business?
NVS

Insider Monkey

2 months ago

What Makes Novartis AG (NVS) a Differentiated Business?

Novartis announces commencement of tender offer to acquire Regulus Therapeutics
NVS

GlobeNewswire

2 months ago

Novartis announces commencement of tender offer to acquire Regulus Therapeutics

NVS

MT Newswires

2 months ago

Market Chatter: Court Denies Novartis' Motion to Dismiss Lawsuit Alleging Asthma Drug Caused Autism

Are You Looking for a High-Growth Dividend Stock?
NVS

Zacks

2 months ago

Are You Looking for a High-Growth Dividend Stock?

Share on Social Networks: